|
Ziftomenib Clinical Trials
9 actively recruiting trials across 5 locations
Also known as: KO-539
Pipeline
Phase 1: 6Phase 3: 1Phase 1/2: 2
Top Sponsors
- Kura Oncology, Inc.5
- M.D. Anderson Cancer Center2
- Tanja Andrea Gruber1
- Massachusetts General Hospital1
Indications
- Cancer9
- Acute Myeloid Leukemia6
- NPM1 Mutation3
- KMT2Ar2
- AML With Mutated NPM12
Gilbert, Arizona3 trials
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Banner MD Anderson Cancer Center
Phase 1/2
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Banner MD Anderson Cancer Center
Phase 1
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Banner MD Anderson Cancer Center
Phase 3
Phoenix, Arizona2 trials
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Mayo Clinic - Phoenix
Phase 1
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Phoenix Children's Hospital
Phase 1/2
Houston, Texas2 trials
A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia
MD Anderson Cancer Center
Phase 1
Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia
The University of Texas M. D. Anderson Cancer Center
Phase 1
Birmingham, Alabama1 trial
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
University of Alabama at Birmingham
Phase 1
Boston, Massachusetts1 trial
Ziftomenib Maintenance Post Allo-HCT
Massachusetts General Hospital
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.